Moderna Inc (NASDAQ:MRNA) shares are trading higher by 7.2% at $163.54 Wednesday afternoon after Deutsche Bank upgraded the stock from Sell to Hold and announced a $175 price target.
Shares of vaccine companies were otherwise trading lower during Tuesday’s session. Over the past 4 trading sessions, Moderna’s stock has fallen approximately 12.6% from the $175 level to the $152 level.
See Also: Why DraftKings Shares Are Ripping Higher Today
Moderna is a commercial-stage biotech that was founded in 2010. The firm’s mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020.
Moderna has a 52-week high of $497.49 and a 52-week low of $117.34.
